Acadia Pharmaceuticals (ACAD) Operating Margin (2010 - 2026)
Acadia Pharmaceuticals' (ACAD) quarterly Operating Margin came in at 1.72% in Q1 2026, down 962.0% year-on-year from 0.2% in Q1 2025, and down 128.12% quarter-over-quarter from 6.12% in Q4 2025.
Acadia Pharmaceuticals (ACAD) Operating Margin (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Operating Margin history runs 17 years deep, the most recent figure standing at 1.72% for Q1 2026.
- On a quarterly basis, Operating Margin fell 962.0% year-over-year to 1.72% in Q1 2026; TTM through Mar 2026 was 7.39%, a 1619.0% decrease from a year earlier, with the FY2025 full-year figure at 9.78%, down 1431.0% from the prior year.
- Operating Margin eased to 1.72% in Q1 2026 per ACAD's latest filing, from 6.12% in the prior quarter.
- Across five years, Operating Margin topped out at 59.13% in Q4 2024 and bottomed at 97.88% in Q1 2022.
- The 5-year median for Operating Margin is 6.12% (2025), against an average of 6.28%.
- Across the five-year window, Operating Margin surged 5264 bps in 2023 and slumped 5301 bps in 2025, its largest moves.
- Year by year, Operating Margin stood at 33.75% in 2022, then surged by 145 bps to 15.12% in 2023, then soared by 291 bps to 59.13% in 2024, then plunged by 90 bps to 6.12% in 2025, then plunged by 128 bps to 1.72% in 2026.
- Per Business Quant, the three latest ACAD Operating Margin figures stand at 1.72% (Q1 2026), 6.12% (Q4 2025), and 12.83% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Acadia Pharmaceuticals | 4.23 Bn | 3.38 Bn | 243.27 Mn | -1.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.72% |
| Dec 31, 2025 | 6.12% |
| Sep 30, 2025 | 12.83% |
| Jun 30, 2025 | 12.24% |
| Mar 31, 2025 | 7.90% |
| Dec 31, 2024 | 59.13% |
| Sep 30, 2024 | 12.64% |
| Jun 30, 2024 | 12.58% |
| Mar 31, 2024 | 7.39% |
| Dec 31, 2023 | 15.12% |
| Sep 30, 2023 | -27.29% |
| Jun 30, 2023 | 1.84% |
| Mar 31, 2023 | -45.23% |
| Dec 31, 2022 | -33.75% |
| Sep 30, 2022 | -23.61% |
| Jun 30, 2022 | -25.01% |
| Mar 31, 2022 | -97.88% |
| Dec 31, 2021 | -34.15% |
| Sep 30, 2021 | -11.63% |
| Jun 30, 2021 | -37.93% |